Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06567600 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
In this phase 2 study, researchers aimed to evaluate the efficacy and safety of low-dose gemcitabine and cisplatin chemotherapy and the immune checkpoint inhibitor PD-1/PD-L1 antibody in patients with advanced and unresectable intrahepatic cholangiocarcinoma.
Trial Details
NCT Number NCT06567600
Lead Sponsor Third Affiliated Hospital, Sun Yat-Sen University
Collaborators: Second Affiliated Hospital of Guangzhou Medical University
Conditions
(from sponsor)		 Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
Related terms Cholangiocarcinoma
Enrollment 43 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov